Melanotan II vs PT-141: Same Origin, Very Different Compounds

Key takeaways:

• Melanotan II (MT-II) and PT-141 (bremelanotide) both act on the melanocortin receptor system, but they were designed for different purposes and have very different receptor selectivity profiles
• MT-II is a non-selective melanocortin receptor agonist that activates MC1R through MC5R -- producing tanning, sexual arousal, appetite suppression, and significant side effects like nausea and mole changes
• PT-141 was engineered from MT-II to selectively target MC3R and MC4R -- the receptors responsible for sexual function -- while minimizing the tanning and appetite effects
• PT-141 is FDA-approved as Vyleesi for hypoactive sexual desire disorder (HSDD) in premenopausal women. MT-II remains an unapproved research peptide with no regulatory clearance anywhere in the world
• The core difference is precision: MT-II is a shotgun that hits every melanocortin receptor. PT-141 is a rifle aimed at sexual function

Important: This article is for educational and informational purposes only. It is not medical advice. Melanotan II is a research compound not approved by the FDA for any human indication. PT-141 (bremelanotide) is FDA-approved only as Vyleesi for HSDD in premenopausal women. Always consult a qualified healthcare provider before considering any peptide protocol. See our full medical disclaimer.

How They Work

The story of these two peptides starts in the same lab. In the 1980s and early 1990s, researchers at the University of Arizona were studying melanocortin receptors -- a family of five receptors (MC1R through MC5R) involved in skin pigmentation, energy regulation, sexual behavior, inflammation, and adrenal function. They developed Melanotan II as a synthetic analog of alpha-melanocyte-stimulating hormone (alpha-MSH), the body's natural pigmentation signal. The goal was to create a sunless tanning agent that could reduce skin cancer risk by darkening the skin without UV exposure.

MT-II worked. It did produce tanning. But it also did a lot of other things, because it activates nearly every melanocortin receptor subtype. MC1R activation drives melanogenesis -- the production and distribution of melanin in the skin. MC3R and MC4R activation in the central nervous system affects sexual arousal and desire. MC4R also plays a role in appetite regulation and energy homeostasis. MC5R is involved in sebaceous gland function. The result is a compound that simultaneously darkens skin, increases libido, suppresses appetite, and causes nausea -- all from the same injection.

The sexual function effects were not expected. During early clinical trials of MT-II for tanning, male subjects reported spontaneous erections unrelated to sexual stimulation (PMID: 10798211). This was a significant finding, because it suggested a central nervous system mechanism for sexual arousal that was distinct from the peripheral vascular mechanism targeted by drugs like sildenafil (Viagra). The erections produced by MT-II originated in the brain, not in the blood vessels of the penis.

This observation led directly to the development of PT-141. Researchers recognized that a compound targeting sexual function would need to be stripped of the tanning, appetite, and other off-target effects that made MT-II impractical as a pharmaceutical product. PT-141 (bremelanotide) is a cyclic heptapeptide -- a modified version of MT-II that was engineered for selectivity toward MC3R and MC4R while significantly reducing affinity for MC1R. The result is a compound that activates the central sexual arousal pathway without meaningfully triggering melanogenesis.

The mechanism by which PT-141 enhances sexual function is fundamentally different from PDE5 inhibitors like Viagra or Cialis. Those drugs work peripherally -- they increase blood flow to erectile tissue by inhibiting an enzyme in blood vessel walls. PT-141 works centrally -- it activates melanocortin receptors in the hypothalamus and limbic system, areas of the brain involved in sexual desire and arousal. This means PT-141 affects desire itself, not just the mechanical blood flow response. That distinction is clinically important, because it means PT-141 can address conditions where desire is absent -- not just conditions where the physical response is impaired.

MT-II's non-selectivity is both its appeal and its liability. Users who want tanning are getting a compound that also affects appetite, sexual function, and nausea pathways. Users who want sexual enhancement are getting a compound that also darkens their skin and changes their moles. Every effect is a package deal, because MT-II does not discriminate between receptor subtypes with any meaningful precision.

What the Research Shows

MT-II has been studied in clinical settings primarily for its melanogenic (tanning) properties. A Phase I trial published in the Journal of the American Academy of Dermatology demonstrated that subcutaneous MT-II administration produced significant increases in skin pigmentation in fair-skinned subjects without UV exposure (PMID: 10798211). The tanning effect was dose-dependent and visually noticeable. However, the trial also revealed the side effect profile that would ultimately prevent MT-II from progressing to approval: nausea, facial flushing, fatigue, and spontaneous penile erections in male subjects.

The sexual function effects of MT-II were explored more directly in subsequent studies. A placebo-controlled crossover study in men with erectile dysfunction found that MT-II administered by subcutaneous injection produced erections in 80% of subjects compared to 20% on placebo (PMID: 10798211). Importantly, these responses occurred in men with both organic and psychogenic erectile dysfunction, suggesting a central mechanism that could work regardless of the underlying cause. But MT-II was never going to become an approved erectile dysfunction drug in its current form -- the tanning, nausea, and other off-target effects were too significant.

PT-141 has a more conventional clinical development history. Palatin Technologies developed bremelanotide through a formal pharmaceutical pipeline. The critical trials were the RECONNECT studies -- two large Phase 3, randomized, double-blind, placebo-controlled trials in premenopausal women with hypoactive sexual desire disorder (HSDD). These trials enrolled over 1,200 women and demonstrated that PT-141 significantly increased the number of satisfying sexual events and sexual desire scores while reducing distress associated with low sexual desire (PMID: 31135760).

Based on the RECONNECT data, the FDA approved bremelanotide (brand name Vyleesi) in June 2019 for the treatment of acquired, generalized HSDD in premenopausal women. This made PT-141 the first melanocortin receptor agonist approved for any sexual health indication and the first centrally acting sexual function drug for women. It is administered as a subcutaneous injection via an autoinjector, taken at least 45 minutes before anticipated sexual activity. The approved dosing is 1.75 mg per injection, with a maximum of one dose per 24 hours and no more than 8 doses per month.

PT-141 has also been studied in men with erectile dysfunction, where it showed efficacy -- including in a subset of men who had failed PDE5 inhibitor therapy (PMID: 15763536). This is a meaningful finding because PDE5 inhibitor non-responders represent a significant unmet medical need. However, PT-141 has not received FDA approval for male sexual dysfunction. The development focus shifted to the female HSDD indication, likely because the male erectile dysfunction market was already dominated by established oral medications.

One additional area of MT-II research worth noting involves appetite suppression. MC4R activation is known to reduce food intake, and MT-II has been studied in the context of obesity and energy regulation. Animal studies have consistently shown that melanocortin receptor agonists reduce feeding behavior (PMID: 17584757). Some MT-II users report noticeable appetite reduction as a side effect. This is not a therapeutic benefit in any approved sense -- it is an off-target effect of MT-II's non-selective receptor activation -- but it does attract attention in weight management circles. PT-141, because of its greater selectivity, does not produce clinically meaningful appetite suppression at the approved dose.

Side Effects and Tolerability

This is where the selectivity difference between these two compounds matters most.

MT-II's side effect profile reflects its broad receptor activity. The most commonly reported effects include nausea (often significant, especially in the first few doses), facial flushing, fatigue, and injection site reactions. The nausea is attributed to melanocortin receptor activation in the area postrema -- a region of the brainstem involved in the vomiting reflex. Many users report that nausea decreases with continued use, but it can be severe enough in initial doses to limit tolerance.

The dermatological effects are the most distinctive and most concerning feature of MT-II. Because MT-II potently activates MC1R, it stimulates melanocytes to produce melanin. This produces the desired tanning effect, but it also causes changes in existing moles and the appearance of new nevi (moles). Multiple case reports have documented the development of new pigmented lesions, darkening and morphological changes in pre-existing moles, and in rare cases, the diagnosis of melanoma in MT-II users (PMID: 25244262). The causal relationship between MT-II and melanoma has not been definitively established -- correlation is not causation, and people who use tanning peptides may also have other risk factors for melanoma, including UV exposure and fair skin type. However, the biological plausibility is strong enough that dermatologists consistently flag MT-II as a concern. Any compound that stimulates melanocyte proliferation and changes nevus morphology warrants serious caution in the context of melanoma risk.

Additional MT-II effects include increases in blood pressure (transient but measurable), spontaneous erections in men (which can be socially problematic and unrelated to sexual stimulation), and changes in skin pigmentation that are uneven or patchy, particularly in areas with pre-existing hyperpigmentation like freckles, scars, or the genitals.

PT-141's side effect profile is narrower, consistent with its more targeted receptor activity. The most common adverse effects reported in the RECONNECT trials were nausea (40% of PT-141 users vs. 1% on placebo), flushing (20%), headache (11%), and injection site reactions (PMID: 31135760). The nausea rate is notable -- it was the most commonly cited reason for discontinuation in clinical trials. The FDA labeling for Vyleesi includes a recommendation to take an antiemetic prior to dosing if nausea was experienced with previous doses.

PT-141 does carry one specific cardiovascular warning. In clinical trials, it caused transient increases in blood pressure of approximately 6 mmHg systolic and 3 mmHg diastolic after dosing, typically resolving within 12 hours. The FDA labeling advises against use in patients with uncontrolled hypertension or known cardiovascular disease. It is also contraindicated in patients taking naltrexone due to a drug interaction concern.

Critically, PT-141 does not cause the mole changes, skin darkening, or melanocyte proliferation concerns associated with MT-II. This is a direct result of its reduced MC1R affinity. For patients whose primary concern is sexual function, this is a significant safety advantage over MT-II.

Cost, Access, and Practical Considerations

The practical landscape for these two compounds could not be more different.

MT-II is sold exclusively through research peptide suppliers and gray-market vendors. It is not available by prescription, is not manufactured under pharmaceutical-grade conditions (in most cases), and is not subject to the quality controls that govern approved medications. A typical vial of MT-II (10 mg lyophilized powder) costs between $20 and $40 from research suppliers. It requires reconstitution with bacteriostatic water, dosing with insulin syringes, and self-injection -- typically subcutaneous. There is no standardized dosing protocol. Community-established dosing ranges typically start at 0.25 mg to 0.5 mg to assess tolerance (primarily nausea), then increase to 0.5 mg to 1.0 mg administered several times per week during a "loading phase" until desired tanning is achieved, followed by less frequent "maintenance" doses. None of this is clinically validated or FDA-sanctioned.

PT-141 is available through two distinct channels. As Vyleesi (brand name), it is available by prescription as a prefilled 1.75 mg autoinjector. The brand-name price is steep -- approximately $800 to $1,000 per dose without insurance, though manufacturer coupons and insurance coverage can reduce this significantly. Each autoinjector is single-use, designed for self-administration in the thigh or abdomen at least 45 minutes before sexual activity.

The second channel is compounded PT-141 (bremelanotide), available from compounding pharmacies with a prescription. Compounded PT-141 typically comes as a lyophilized powder requiring reconstitution, similar to MT-II in format but with the legal legitimacy of a prescription and the quality assurance of a licensed compounding pharmacy. Compounded PT-141 is significantly cheaper than brand-name Vyleesi -- often in the range of $50 to $150 for a multi-dose vial -- and allows for dose customization under physician guidance. Compounded bremelanotide is used off-label for both men and women, while Vyleesi is approved only for premenopausal women.

Storage requirements are similar for both compounds in their lyophilized form: refrigerated (2-8 degrees Celsius) both before and after reconstitution. Reconstituted solutions should be used within 3 to 4 weeks. Both require standard sterile injection technique when self-administered. For guidance on reconstitution and injection, see our bacteriostatic water guide.

A practical consideration that deserves emphasis: purity verification is especially important with MT-II. Because it exists entirely outside the pharmaceutical regulatory system, there is no guarantee that a vial labeled "Melanotan II" contains melanotan II at the stated purity and concentration. Third-party certificates of analysis (COAs) via HPLC and mass spectrometry are the minimum standard for verification. PT-141 obtained through a licensed compounding pharmacy or as brand-name Vyleesi does not carry this uncertainty.

One more distinction worth noting: PT-141 has dosing limits built into its FDA labeling. No more than one dose per 24 hours and no more than 8 doses per month. These limits were established based on clinical trial data regarding blood pressure effects and nausea management. MT-II has no such established guidelines, and dosing frequency in the user community varies widely -- from daily loading protocols to weekly maintenance doses.

The Bottom Line

MT-II and PT-141 share a common ancestor but serve fundamentally different purposes. They are not interchangeable, and choosing between them depends entirely on what you are trying to accomplish and how much risk you are willing to accept.

MT-II is a blunt instrument. It activates the full melanocortin receptor family, producing tanning, sexual enhancement, appetite suppression, and a battery of side effects -- including mole changes that raise legitimate dermatological concerns. It is cheap, widely available from research suppliers, and remains popular in bodybuilding, fitness, and tanning communities. But it is not FDA-approved, not manufactured to pharmaceutical standards, and not backed by the kind of clinical trial data that would establish a well-characterized safety profile for long-term use.

PT-141 is a refined tool. It was deliberately engineered from MT-II to target the sexual function pathway while stripping away the tanning, appetite, and melanocyte-proliferation effects. It has gone through the full pharmaceutical development process, including large Phase 3 trials, and has received FDA approval for a specific indication (HSDD in premenopausal women). Its side effect profile is narrower and better characterized. It is more expensive in brand-name form, but accessible at moderate cost through compounding pharmacies.

For individuals whose primary interest is tanning, MT-II is the only compound between the two that meaningfully activates MC1R. PT-141 will not darken your skin. But pursuing a tan through MT-II means accepting the full package of non-selective melanocortin activation -- including the nausea, the mole changes, and the unknowns of long-term melanocyte stimulation.

For individuals whose primary interest is sexual function, PT-141 offers a targeted, clinically validated mechanism with a well-characterized safety profile. It works through a fundamentally different pathway than PDE5 inhibitors, addressing desire rather than just blood flow. It is available as a legal prescription product, which means physician oversight and pharmaceutical-grade manufacturing.

The evolution from MT-II to PT-141 is a textbook case of pharmacological refinement -- taking a compound that hit too many targets and engineering a more selective version for a specific therapeutic purpose. Both compounds exist in the marketplace. But they represent very different tradeoffs between efficacy, selectivity, safety, and regulatory legitimacy.

---

Medical Disclaimer: The information on this website is for educational and informational purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide protocol, medication, or supplement regimen. Individual results vary. The editorial team shares published research and educational content -- not medical recommendations.

Sources

1. Melanocortin receptor agonists and penile erection -- early MT-II clinical data -- Archives of Sexual Behavior, 2000
2. Bremelanotide for HSDD in premenopausal women (RECONNECT Phase 3) -- Obstetrics & Gynecology, 2019
3. PT-141 efficacy in men with erectile dysfunction including PDE5 inhibitor failures -- International Journal of Impotence Research, 2005
4. Melanocortin receptor agonists and appetite/energy regulation -- Peptides, 2007
5. Melanotan II-associated melanocytic nevus changes and melanoma concerns -- British Journal of Dermatology, 2014